RxDoctor Payments Data

Jesse Morriss, MD

Internal Medicine · Dothan, ALNPI 1063481273

Payments from drug & device makers

$7,669in general payments, 2019–2025

Across 558 payments — averaging $13.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$865
  • Johnson & Johnson$781
  • AstraZeneca$687
  • GSK$622
  • Novo Nordisk$582
  • Pfizer$421
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$7,644100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,669 in reported general payments places this provider in the 85th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$699,879
Medicare patients
1,139
Services billed
16,651

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,292$430,890
XareltoRivaroxaban534$223,088
TrulicityDulaglutide162$174,987
OzempicSemaglutide161$168,884
JanuviaSitagliptin Phosphate496$167,242
MounjaroTirzepatide130$146,096
MyrbetriqMirabegron364$119,998
FarxigaDapagliflozin Propanediol116$76,655
EntrestoSacubitril/Valsartan252$74,274
LinzessLinaclotide174$70,645
Trelegy ElliptaFluticasone/Umeclidin/Vilanter82$59,763
Potassium Chloride2,008$41,440
Breo ElliptaFluticasone/Vilanterol89$37,680
JardianceEmpagliflozin68$37,085
NuedextaDextromethorphan Hbr/Quinidine46$31,296

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$421$430,8901,292 claims
Lilly USA, LLCTrulicity, Mounjaro$259$321,083292 claims
Johnson & JohnsonXarelto, Invokana$781$241,583559 claims
MerckJanuvia, Janumet, Lagevrio (Eua)$49$206,250544 claims
Novo NordiskOzempic$582$168,884161 claims
AstraZenecaFarxiga, Lokelma, Brilinta$687$127,929236 claims
Astellas Pharma US IncMyrbetriq$202$119,998364 claims
AbbVieLinzess, Creon, Namzaric$865$106,540265 claims
GSKTrelegy Ellipta, Breo Ellipta$622$97,443171 claims
NovartisEntresto$115$74,274252 claims
Boehringer IngelheimJardiance$141$37,08568 claims
Avanir Pharmaceuticals, Inc.Nuedexta$13$31,29646 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Dothan

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →